Efficacy News and Research

RSS

UChicago researchers awarded NIH grants to develop novel medications for sleep apnea, asthma

Two research teams based at the University of Chicago have received prestigious grants from the National Institutes of Health to develop novel medications to treat sleep apnea and asthma.

21 Jan 2015

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Researchers have tracked the genetic mutations that have occurred in the Ebola virus during the last four decades. Their findings, published in mBio, the online open-access journal of the American Society for Microbiology, identified changes in the current West African outbreak strain that could potentially interfere with experimental, sequence-based therapeutics.

21 Jan 2015

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Combination therapy with amrubicin and carboplatin is moderately effective in patients with advanced thymic carcinoma, a Japanese study finds, but invasive thymoma patients do not benefit from this regimen.

20 Jan 2015

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Individuals with advanced non-small-cell lung cancer who have rare or complex epidermal growth factor receptor mutations have inferior outcomes in response to EGFR–tyrosine kinase inhibitor treatment compared with those with common mutations, research indicates.

20 Jan 2015

Effective vaccine booster schedules needed to fight against whooping cough resurgence

A key to victory in battle, according to Chinese general and military strategist Sun Tzu, is to know your enemy. In the current fight against whooping cough resurgence, perhaps the biggest obstacle is an incomplete understanding of its underlying causes, according to a University of Michigan population ecologist.

20 Jan 2015

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy.

20 Jan 2015

Combining insecticide-treated bed nets and vaccines may worsen malaria

Combining insecticide-treated bed nets with vaccines and other control measures may provide the best chance at eliminating malaria, which killed nearly 600,000 people worldwide in 2013, most of them African children.

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A., granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa.

19 Jan 2015

Peripheral muscles weakened in PAH patients

Patients with pulmonary arterial hypertension have peripheral muscle weakness that is independent of impairments in their respiratory muscles, research shows.

16 Jan 2015

Study: Century-old drug may help treat autism

Autism spectrum disorders (ASD) affect 1 to 2 percent of children in the United States. Hundreds of genetic and environmental factors have been shown to increase the risk of ASD. Researchers at UC San Diego School of Medicine previously reported that a drug used for almost a century to treat trypanosomiasis, or sleeping sickness, reversed environmental autism-like symptoms in mice.

16 Jan 2015

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.

16 Jan 2015

$New device holds promise for improving the delivery of stem cell therapy for non-healing fractures$

New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

A new device that can rapidly concentrate and extract young cells from irrigation fluid used during orthopaedic surgery holds promise for improving the delivery of stem cell therapy in cases of non-healing fractures. UC Davis surgeons plan to launch a "proof-of-concept" clinical trial to test the safety and efficacy of the device in the coming months.

16 Jan 2015

First medical device approved for treatment of obesity

The United States Food and Drug Administration approved EnteroMedic's VBLOC vagal blocking therapy, delivered via the Maestro System, which is the first medical device approved for obesity treatment that targets the nerve pathway between the brain and the stomach.

15 Jan 2015

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

Reducing fears key to success of CBT or GET in people with chronic fatigue syndrome

Reducing fears that exercise or activity will make symptoms worse is one of the most important factors determining the success of cognitive behaviour therapy (CBT) or graded exercise therapy (GET) in reducing fatigue and improving physical function in people with chronic fatigue syndrome (CFS), according to new analysis of data from the PACE trial, reported in The Lancet Psychiatry journal.

14 Jan 2015

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.

14 Jan 2015

Researchers evaluate fitness apps that help users modify their physical activities

Fitness applications (apps) use behavior change techniques (BCTs) to help users modify their physical activities, but which apps and which techniques are most effective? In a study in the American Journal of Preventive Medicine, researchers evaluated 100 top-ranked physical activity apps and analyzed which BCTs are being used in these apps. They determined that at present BCTs have been only narrowly implemented in physical activity apps.

14 Jan 2015

Research findings may lead to new treatment for hypothyroidism

An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.

14 Jan 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

Efficacy News and Research

UChicago researchers awarded NIH grants to develop novel medications for sleep apnea, asthma

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Effective vaccine booster schedules needed to fight against whooping cough resurgence

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Combining insecticide-treated bed nets and vaccines may worsen malaria

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

Peripheral muscles weakened in PAH patients

Study: Century-old drug may help treat autism

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

New device holds promise for improving the delivery of stem cell therapy for non-healing fractures

First medical device approved for treatment of obesity

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Reducing fears key to success of CBT or GET in people with chronic fatigue syndrome

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Researchers evaluate fitness apps that help users modify their physical activities

Research findings may lead to new treatment for hypothyroidism

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News